November 10, 2016 08:51 AM ESTUpdated 10:01 AM
News Briefing

Adap­ti­m­mune surges af­ter FDA lifts par­tial hold; An­thera tanks on PhI­II flop; Kad­mon ax­es staffers in re­struc­tur­ing

Shehla Shakoor

Managing Director

Adap­ti­m­mune stock $ADAP surged 14% af­ter the com­pa­ny re­vealed in its Q3 up­date that the FDA had lift­ed its par­tial hold on its lead …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times